Acceleron Pharma Inc (NASDAQ:XLRN) Director Jean George sold 105,122 shares of the business’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $35.73, for a total value of $3,756,009.06. Following the sale, the director now owns 1,250 shares in the company, valued at $44,662.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Acceleron Pharma Inc (NASDAQ:XLRN) opened at $38.24 on Thursday. Acceleron Pharma Inc has a 1-year low of $23.07 and a 1-year high of $40.35.

Acceleron Pharma (NASDAQ:XLRN) last released its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.67) by $0.02. Acceleron Pharma had a negative return on equity of 37.32% and a negative net margin of 844.43%. The company had revenue of $3.00 million during the quarter, compared to analysts’ expectations of $3.52 million. During the same period in the previous year, the firm posted ($0.55) earnings per share. The business’s revenue for the quarter was up .0% compared to the same quarter last year. equities analysts anticipate that Acceleron Pharma Inc will post -2.65 EPS for the current fiscal year.

A number of analysts have commented on the company. Oppenheimer reiterated a “hold” rating on shares of Acceleron Pharma in a research report on Monday, December 11th. HC Wainwright reiterated a “buy” rating and set a $62.00 target price on shares of Acceleron Pharma in a research report on Monday, December 11th. Credit Suisse Group set a $51.00 target price on Acceleron Pharma and gave the stock a “buy” rating in a research report on Tuesday, November 14th. Royal Bank of Canada reiterated a “hold” rating on shares of Acceleron Pharma in a research report on Thursday, November 2nd. Finally, ValuEngine downgraded Acceleron Pharma from a “hold” rating to a “sell” rating in a research report on Friday, October 6th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. Acceleron Pharma presently has an average rating of “Buy” and a consensus price target of $44.56.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in XLRN. Perceptive Advisors LLC raised its holdings in shares of Acceleron Pharma by 127.2% in the third quarter. Perceptive Advisors LLC now owns 1,616,259 shares of the biopharmaceutical company’s stock worth $60,319,000 after acquiring an additional 905,000 shares during the last quarter. Westfield Capital Management Co. LP increased its stake in Acceleron Pharma by 46.6% in the second quarter. Westfield Capital Management Co. LP now owns 1,682,359 shares of the biopharmaceutical company’s stock valued at $51,127,000 after purchasing an additional 534,440 shares during the last quarter. Sectoral Asset Management Inc increased its stake in Acceleron Pharma by 378.2% in the second quarter. Sectoral Asset Management Inc now owns 604,499 shares of the biopharmaceutical company’s stock valued at $18,371,000 after purchasing an additional 478,099 shares during the last quarter. BlackRock Inc. increased its stake in Acceleron Pharma by 9.0% in the second quarter. BlackRock Inc. now owns 4,005,228 shares of the biopharmaceutical company’s stock valued at $121,719,000 after purchasing an additional 330,635 shares during the last quarter. Finally, AXA acquired a new position in Acceleron Pharma in the second quarter valued at $9,833,000. 85.70% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This story was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/12/21/acceleron-pharma-inc-xlrn-director-sells-3756009-06-in-stock.html.

Acceleron Pharma Company Profile

Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.

Insider Buying and Selling by Quarter for Acceleron Pharma (NASDAQ:XLRN)

Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.